Erwa H H, Haseeb M A, Idris A A, Lapeyssonnie L, Sanborn W R, Sippel J E
Bull World Health Organ. 1973;49(3):301-5.
Vaccination against cerebrospinal meningitis (CSM) has regained interest with the use of capsular polysaccharides (or polyosides) of the meningococcus as specific immunizing agents. These compounds proved to be effective in the USA against meningitis caused by Neisseria meningitidis serotype C. This study considers whether the polysaccharides of the serotype A meningococcus, which is prevalent in the African CSM belt, could be protective in epidemic conditions. Taking advantage of the usual seasonal peak of CSM cases, controlled field trials were undertaken in the Sudan early in 1973. 21 640 persons were vaccinated, half of them with a meningococcal polyoside A vaccine and the other half with tetanus toxoid as a placebo. In the former group there were no cases of meningitis, whereas in the latter 10 cases were reported, of which 7 were confirmed by laboratory tests. These studies indicate that the meningococcal polyoside A vaccine is efficient in epidemic conditions and could be used to control outbreaks of meningococcal meningitis.
随着将脑膜炎球菌的荚膜多糖（或多聚糖）用作特异性免疫剂，针对脑脊膜炎（CSM）的疫苗接种重新受到关注。这些化合物在美国被证明对由脑膜炎奈瑟菌C血清型引起的脑膜炎有效。本研究探讨了在非洲脑脊膜炎带流行的A血清型脑膜炎球菌的多糖在流行情况下是否具有保护作用。利用脑脊膜炎病例通常的季节性高峰，1973年初在苏丹进行了对照现场试验。21640人接种了疫苗，其中一半接种了A群脑膜炎球菌多聚糖疫苗，另一半接种破伤风类毒素作为安慰剂。在前一组中没有脑膜炎病例，而在后一组中报告了10例病例，其中7例经实验室检测确诊。这些研究表明，A群脑膜炎球菌多聚糖疫苗在流行情况下是有效的，可用于控制脑膜炎球菌性脑膜炎的暴发。
